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Abstract
Objective: To identify the overall survival and prognostic factors of malignant lymphoma of the oral cavity and 
the maxillofacial region.
Study Design: Clinical records data were obtained in order to determine overall survival at 2 and 5 years, the 
individual survival percentage of each possible prognostic factor with the actuarial technique, and the survival re-
garding the possible prognostic factors with the actuarial technique and the Log-rank and Cox’s regression tests. 
Results: Of 151 subjects, an overall survival was 60% at 2 years, and 45% at 5 years. The multivariate analysis 
demonstrated statistically significant differences for clinical stage (p=0.002), extranodal involvement (p=0.030), 
presence of human immunodeficiency virus (p=0.032), and presence of Epstein-Barr virus (p=0.010). 
Conclusion: The advanced clinical stage and the larger number of involved extranodular sites are related to a 
lower overall survival, as well as, the presence of previous infections such as the human immunodeficiency and 
the Epstein-Barr virus.
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Introduction
Malignant tumors of the oral cavity are infrequent, re-
presenting only 5% of all those occurring in the human 
body. Among malignant tumors of the oral cavity, squa-
mous cell carcinomas are the most frequent type (90 to 
98%), and malignant lymphomas are the most outstan-
ding among the remaining 2 to 10%. These lymphomas 
are neoplasms characterized by the clonal proliferation 
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of lymphocytes and of their cell precursors (1), and of 
lymphocyte cell lines (2). The only feature shared by 
this group of is that they arise as the result of a somatic 
mutation of a lymphocyte progenitor (3). 
ML are a heterogeneous group of neoplasms that are 
classically divided into two subgroups, Hodgkin Lym-
phoma (HL) and the non-Hodgkin Lymphoma (NHL) 
(2,4) due to their biological, histological, immunophe-
notypical differences, and clinical behavior patterns 
(1).
In general terms, NHL has a worse prognosis than HL, 
because when it is diagnosed, patients are often already 
at an advanced stage of the disease, and these neoplasms 
are more aggressive (5). 
Over the years, many schemes of classification have 
been described the first based only in the cell morpholo-
gy. In 1995 the World Health Organization (WHO) star-
ted the project of classification of haematopoietic and 
lymphoid-tissue tumors published in 2001. Since then, it 
has been accepted by most pathologists and clinicians as 
the first world system of consensus classification, which 
is based on the combination of morphological, immu-
nophenotypical data, molecular genetics, and clinical 
aspects. The classification also helps predict the clinical 
aggressiveness of the subtype. The classification was 
re-edited by the WHO in 2008 with the participation 
from the Hematopathology Society and the European 
Association of Hematopathologists. A combination of 
morphological, immunophenotypical data, genetic cha-
racteristics, and clinical syndromes were included, in 
addition to defining new entities and giving solutions 
to diagnosis accuracy problems (6), this included the 
recognition of small clonal lymphoid populations and 
the identification of diseases characterized by the par-
ticipation of certain anatomical sites or other clinical 
characteristics such as the age (7). 
In general, HL corresponds to approximately 14% of 
all the lymphomas (8) and NHL to 86% of lymphomas 
(9,10). Usually, lymphomas first appear as nodal disease 
most commonly within the cervical and mediastinal no-
des, extranodal lymphomas is not as common; whereas, 
NHL appears commonly in extranodal locations (10,11) 
between 24% (12) and 48% (11).
NHL occur in 3.5% of all the malignant neoplasms of 
the oral cavity and the jaw bones (8,13).
The causes of the NHL are uncertain (2). Risk factors 
include exposure to pesticides and radiation, long-term 
immunosuppresion, and autoimmune diseases such 
as the rheumatoid arthritis, systemic lupus erythema-
tosus, and the Sjögren syndrome (14). Several viruses 
have been suggested as potential causes for this disea-
se (2), including the Epstein-Barr virus (EBV), Human 
T-cell lymphotropic virus 1 (HTLV-1), Human immu-
nodeficiency virus (HIV), Human Herpes virus type 8 
(HHV-8, HVSK) (15) and Hepatitis B, C and G virus 
(HBV, HCV and HGV) have all been related to a greater 
risk of NHL (16) and can act in multiple lymphocyte 
cell clones, contributing to their neoplastic transforma-
tion (17). Other microorganisms involved in the genesis 
of the NHL are Helicobacter pylori and the Chlamydia 
(16).
In the oral cavity NHL corresponds to its extranodal 
presentation (8) and can occur in the soft tissues or bo-
nes. The most common sites being the soft tissues of the 
oral cavity, the palatal mucosa, the gingiva, the tongue, 
the cheek, the floor of the mouth and the lips and in the 
maxillofacial region, the salivary glands and the maxi-
llary sinuses (8). 
The systemic signs and symptoms include fever of an 
unknown origin (> 38ºC), inexplicable weight loss (> 
10% of the body weight in the last 6 months before ad-
mission), night sweats (1,18), visceral pain and malaise 
(“B” symptoms), identified in 40% of the new cases (18). 
Patients with oral lymphoma rarely present withfever or 
weight loss (8,19) and therefore they are almost never 
accompanied by “B” symptoms (13,19).
The classification of the International working formula-
tion for clinical usage (20) grouped NHL according to 
their increasing aggressiveness (low level, intermediate 
level and high level). Nevertheless, its usage has been 
gradually abandoned and replaced by the WHO’s clas-
sification.
Oral lesions of NHL can simulate inflammatory pro-
cesses. The first important factor in the diagnosis of 
extranodal lymphoma in the oral cavity is to determine 
if the lesion is a tooth abscess, a periodontal infection a 
primary lymphoma of the oral cavity, or a more wides-
pread manifestation of the disease (17).
In the region of the head and the neck NHL must be 
considered as a differential diagnosis when there is an 
inexplicable toothache, insensitivity, tooth mobility, in-
crease of volume, ulceration, mass in an extraction al-
veolus or ill-defined lytic bone alteration (17).
The system most widely used for the clinical stage of 
ML is Ann Arbor’s based on the anatomical extent of 
the lesion, the number of tumor sites (nodal and extra-
nodal), and the location (8). NHL staging is important 
for the therapy as well as to determine prognosis. 
Several studies have tried to identify prognostic factors 
for the NHL. The International Prognostic Index (IPI) 
is the most widely used (21), and it incorporates several 
parameters that have been developed and validated in 
order to provide relevant prognostic information. These 
parameters are (22): age ≥ 60 years old, clinical stage 
(III or IV), the number of extranodal site involvement 
of > 1 site, performance status ≥ 2 and elevated serum 
concentration of Lactate Dehydrogenase (LDH). 
Few NHL survival and prognostic factor studies have 
been carried out in the oral cavity. Since dental sur-
geons play an important role in the early detection of 
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ML, they should be familiarized with the clinical and 
pathological characteristics of this disease in order to 
have a proper diagnosis. On the other hand, measuring 
and interpreting the characteristics of an ML already in 
place is essential to predict the survival of the patient. 
This study aims to identify the overall survival (OS) 
and prognostic factors of ML of the oral cavity and the 
maxillofacial region.
Material and Methods
The design of the present study is of observational, des-
criptive, transversal, and retrospective in type. Subjects 
included in this study were ones who obtained a primary 
diagnosis of lymphoma of the oral cavity or the maxillo-
facial region seen in the Cancer Hospital, A. C. Camargo, 
São Paulo, Brazil, over the period of January 1980 to De-
cember 2005. The diagnosis of lymphoma was confirmed 
histologically and immunophenotypically, with almost 
42% (63 cases) of the paraffin blocks being re-evaluated, 
while in other cases, their equivalent diagnoses were gi-
ven according to Harris et al. (23). Clinical records with 
incomplete data were excluded. 
In the analysis OS was determined and defined as the 
percentage of subjects who remain alive over the period 
comprised between the beginning of the treatment to the 
last visit to the doctor s´ office, or date of death in years.
For the analysis of prognostic factors the following va-
riables were considered: age, gender, presence of HIV 
and EBV, signs and symptoms, location, size, WHO’s 
diagnosis, histological type of malignancy, clinical 
stage, IPI, performance status, serum concentration 
of LDH, extranodal involvement, treatment, follow-up 
condition, and follow-up time.
Statistical analysis
The collected data were transferred to a Microsoft Ex-
cel program. Then the analysis was carried out with the 
assistance of the statistical program SPSS (Statistical 
Package for Social Sciences) version 17.0 for Windows 
(SPSS, Chicago, IL, USA).
OS analysis was calculated through two statistical tests: 
1) the actuarial technique (mortality tables) in order to 
find the OS percentage at 2 and at 5 years and the indi-
vidual survival percentage of each possible prognostic 
factor 2) Kaplan Meier’s limit-product method to deter-
mine the survival regarding each possible prognostic 
factor.
The analysis of prognostic factors was performed in 
two ways: 1) univariate analysis, with the Log-rank test 
(Mantel-Cox) to determine the individual statistical sig-
nificance of the survival differences of Kaplan Meier’s 
limit-product and 2) multivariate analysis, with Cox’s 
regression model, being all the variables considered.
All values found through the different statistical tests 
were considered with significance from 0.05 (p < 0.05).
Tables and figures were elaborated in the same Micro-
soft Excel program. The analysis was carried out in a 
computer with Operative System Windows XP (Was-
hington, USA).
Results
Between January 1980 to December 2005, 3513 new 
cases of lymphomas were found, of which 4.3% (151) 
occurred at the level of oral cavity and maxillofacial 
region. Of these 151 lymphomas, the largest number 
(27.81%) occurred in patients 61 to 70 years old, and 
53.64% were male. Tonsil was the most frequent loca-
tion (43.05%), followed by parotid gland (13.91%) and 
palate (8.61%).
An overall survival was found at 2 years of 60% and at 5 
years of 45%, of the 151 lymphomas tested (Fig. 1).
In table 1 the OS at 2 years and at 5 years are descri-
bed in detail with corresponding possible prognostic 
factors.
Survival of 74% and 58% was found at 2 years and at 5 
years in subjects in stage I or II disease, and 38% and 
26% in stages III and IV disease, respectively, which 
had a statistical significance in a univariate as well as 
a multivariate analysis. Subjects with only one affec-
ted extranodal site had survival rates of 89% and 73% 
at 2 and 5 years, respectively; whereas, subjects with a 
greater number of sites involved had survival rates of 
51% and 38%, respectively. These values were also sta-
tistically significant in a univariate, as well as, multiva-
riate analysis. The presence of HIV was also evaluated 
as a possible prognostic factor regarding survival, and 
values of 61% and 47% at 2 years and 5 years, respecti-
vely, were found in patients without HIV. Alternatively, 
patients with HIV infection had a survival at 2 years 
of 25%, but survival over 5 years was not observed. 
The differences found were statistically significant in 
a multivariate analysis. Presence of EBV was also eva-
luated with regard to survival; a survival at 2 years of 
60% and at 5 years of 46%, respectively was found in 
non-infected subjects. Data from infected subjects were 
censored, therefore percentages of survival could not 
be obtained. With regard to this variable, there was no 
statistically significant univariate difference, but multi-
variate difference was found (Fig. 2).
The accrued proportion of survival up to 10 years is 
described in table 2. The risk factors influencing survi-
val according to the adjusted model of Cox’s test (Ha-
zard Ratio) showed that patients with a clinical stage I 
or II have 0.531 times more probability of survival than 
patients with a clinical stage III or IV. Patients with a 
number of extranodal sites involved less than or equal to 
1 have 0.586 times more probability of survival than pa-
tients with a number of extranodal sites involved greater 
than 1. Patients with no presence of HIV infection have 
0.678 times more probability of survival than patients 
with HIV infection; and the patients with no presence 
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of EBV infection have 0.937 times more probability of 
survival than patients with EBV infection. These data 
are shown in table 3.
Discussion
Regarding lymphomas found in the head and the neck 
2.2% of them are primarily in the oral cavity or the 
maxillofacial region. Of intraoral malignant lesions 
3.5% are lymphomas (8). All of our 151 study subjects 
were NHL. The percentage of OS found from the ca-
ses in this study was 60% and 45% at 2 and 5 years, 
respectively. When comparing the value obtained at 5 
years, OS was much lower than the rate of 73% found by 
Rowley et al. (24) for HL and 65% for NHL extranodal 
found by Economopoulos et al. (25) Perhaps, this is due 
to fact that both studies were carried out in the head and 
the neck with a greater probability of cervical node level 
involvement.
In this series, no statistical significance was found in an 
univariate, as well as, multivariate analysis of OS com-
paring age, gender, signs and symptoms, size, WHO’s 
diagnosis, and/or histological type of malignancy.
In the present report there was a better OS in lympho-
mas located in the salivary glands, this could be related 
to the fact that in these cases the neoplasm tends to be 
more localized (65% at 5 years, in comparison with the 
locations in maxillary bones, palatine tonsil, soft tissues 
of oral cavity and maxillary sinus, which presented OS 
at 5 years of 55%, 42%, 39% and 30%, respectively). 
Nevertheless, these differences were not statistically 
significant.
Regarding the specific diagnosis as in other studies 
(26) no significant differences were found with regard 
to OS, although it has been reported that diffuse large 
B-cell lymphoma (DLBCL) had a survival at 5 years of 
30%, whereas in the follicular lymphoma (FL) OS was 
reported as 70% (27). This could be related to actual 
therapeutic schemes that have improved the OS of ag-
gressive NHL.
In Angiero et al. (17) and Economopoulos et al. (25) stu-
dies it has been reported that prognosis is influenced by 
the histological level of aggressiveness. In the last study 
mentioned, patients with low-level NHL had a 5 year 
survival rate of 83% compared to 52% for subjects who 
had the high-level histological subtype. In the present 
report no statistical significance was found at the his-
tological level. In recent years, the WHO classification 
Fig. 1. Overall survival curve for patients with lymphoma of the oral cavity and the maxillofacial region, seen in the Cancer Hospital, A. 
C. Camargo, over the period between January 1980 and December 2005. 
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Risk Factors    Survival at  2 years (%) 
Survival at 
5 years (%) 
p value 
according to Log 
Rank
(Univariate) 
p value 
according to Cox 
(Multivariate) 
Age ? 60 61  49  0.280   0.265  
 > 60 58  41      
Gender Female 67 54  0.321   0.351  
 Male 54  38      
Location Oral cavity 58  39  0.500  0.178  
 Palatine tonsil 56  42      
 Maxillary bones 55  55      
 Maxillary sinus 51  30      
 Salivary glands 76  65      
Size of lesion ? 4 cm 62  47  0.663  0.740  > 4 cm 49  41      
Increased volume No 62  50  0.327  0.460  Yes 59  44      
Pain No 60  49  0.619  0.306  
 Yes 56  30      
Local symptoms No 60  45  0.741  0.379  Yes 50  50      
General symptoms No 62  49  0.211  0.652  Yes 54  37      
WHO diagnosis LNH 63  63  0.969  0.850  
DLBCL 60  40      
 FL 47  43      
 BL 54  47      
 MALT 68  47      
 CLL/SLL 67  37      
 MCL 75  58      
 T/NK 45  45      
HIV No 61  47  0.036 * 0.032 * 
 Yes 25  00      
EBV No 60  46  0.094  0.010 * 
 Yes --  --      
Helicobacter pylori No 60  45  0.628  0.271  Yes 50  50      
Clinical stage Clinical stage I and II 74  58  0.000 * 0.002 * Clinical stage III and IV 38  26      
IPI 0 100  100  0.000 * 0.387  
 1 82  60      
 2 77  65      
 3 54  33      
 4 30  27      
 5 53  18      
Performance status ? 1 65  51  0.019 * 0.746  
? 2 44  29      
LDH ? 200 U/L 85  73  0.010 * 0.118  
 > 200 U/L 55  41      
Extranodal
involvement 
? 1 89  73  0.000 * 0.030 * 
> 1 51  38      
Treatment Cht 59  45  0.003 * 0.145  
 Cht + Rt 58  43      
 Rt 61  46      
 Cht + Rt + Sg 100  100      
 Cht + Sg 100  100      
 Sg + Rt 33  00      
 Sg --  --      
 No treatment --  --      
Table 1. Survival percentage at 2 and 5 years evaluated for possible prognostic factors in subjects with lymphoma of the oral 
cavity and the maxillofacial region.
* statistically significant value
NHL non-Hodgkin Lymphoma; DLBCL Diffuse Large B-Cell Lymphoma; FL Follicular Lymphoma; BL Burkitt’s Lymphoma; 
MALT Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; CLL/SLL Chronic Lymphocytic Leu-
kemia and Small Lymphocytic Lymphoma; MCL Mantle Cell Lymphoma; T/NK Extranodal NK/T-Cell Lymphoma, nasal type; 
HIV Human Immunodeficiency virus; EBV Epstein-Barr virus; IPI International Prognostic Index; LDH Lactate Dehydroge-
nase; Cht Chemotherapy; Rt Radiotherapy; Sg Surgery.
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of hematological neoplastic disease has been reported 
individually and each has differing clinical factors and 
evolution. So these diseases are not grouped according 
to their aggressiveness.
Several reports have found that the survival prognosis 
gets worse with clinical stage (3,17,28). This is in line 
with the present study in which patients present a lower 
survival percentage as the clinical stage increases (74% 
and 58% at 2 and 5 years in stages I or II, respectively, 
and of 38% and 26% in stages III or IV), both individua-
lly and jointly, with statistically significant differences.
Mok et al. (22) found 5-year survival rates for nodal lym-
phoma and extranodal lymphoma of 57.4% and 52.1%, 
respectively. Moreover, the number of extranodal sites 
was not a significant predictive variable (p = 0.805). In 
the present study; however, the number of extranodal 
sites involved had a significant relevance with a p < 
0.000 value when this criteria was evaluated in a univa-
riate analysis and a p = 0.030 value when evaluated with 
multivariate analysis. A survival of 73% at 5 years was 
found when the subjects presented with an extranodal 
site affected and at 38% when the patient presented with 
Fig. 2. Mortality tables, for subjects with lymphoma of the oral cavity and the maxillofacial region, seen in the Cancer Hospital, A. C. Cama-
rgo, over the period between January 1980 and December 2005.
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more than one extranodal site involved. The difference 
can be explained by the statistical analysis because the 
variable is influenced by clinical stage.
In this study, the survival at 5 years in patients with 
normal serum concentration of LDH was 73% and 41% 
when LDH was elevated, these values were statistically 
significant when evaluated with a univariate analysis. 
These results are similar to those obtained in the Mok et 
al. (22) study in which the rates of survival at 5 years for 
the subjects with extranodal lymphoma who had normal 
and abnormal LDH were 77.3% and 44.9%, respectively 
(p < 0.001). These data confirm the value of LDH as a 
prognostic factor. 
Treatment had an influence on OS (p = 0.003) in a uni-
variate analysis. Based on a review of 53 patients with 
NHL of the head and neck, Ruijs et al. (29), suggested 
that radiotherapy alone is the adequate treatment for 
localized lymphoma while chemotherapy is preferable 
for patients with disseminated lymphoma. According to 
Mok et al. (22) the chemotherapy treatment regime does 
not affect the OS of subjects with a p = 0.715 and a p = 
0.41 respectively.
In the Tanaka et al. (30) study 104 subjects with lympho-
ma and HIV infection had an OS at 4 years of 35.8%, 
the variables with significant influence on OS: previous 
HIV infection and an intermediate-high risk value of 
Nº of patients 
Time
(years) 
At the 
beginning 
of the 
interval
Censured Lost
Cumulative
proportions of 
survival
0 - 1 151 19 39 0.72 
1 - 2 93 6 16 0.60 
2 - 3 71 5 8 0.53 
3 - 4 58 7 3 0.50 
4 - 5 48 6 4 0.45 
5 - 6 38 7 3 0.41 
6 - 7 28 2 3 0.37 
7 - 8 23 0 1 0.35 
8 - 9 22 1 0 0.35 
9 - 10 21 0 0 0.35 
Table 2. Cumulative survival for subjects with lymphoma of the oral cavity and the maxillofacial 
region.
Variable Analyzed Hazard Ratio
Confidence Interval 
95% p value 
Clinical stage  0.288-0.764 0.002* 
              I and II 0.469   
              III and IV 1.0   
Extranodal involvement  0.187-0.918 0.030* 
              ? 1 0.414   
              > 1 1.0   
Presence of HIV  0.114-0.907 0.032* 
               No 0.322   
               Yes 1.0   
Presence of EBV  0.008-0.521 0.010* 
               No 0.063   
               Yes 1.0   
Table 3. Analysis of potential risk factors associated with survival for subjects with lymphoma of the 
oral cavity and the maxillofacial region, according to multivariate Hazard Ratio of Cox analysis.
* statistically significant value.
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the IPI. In this study, similar results were found; pa-
tients with HIV infection had a quite low OS of 25% at 
2 years.
In brief, the following prognostic factors of survival in 
patients with lymphoma in the oral cavity and the maxi-
llofacial region were found in this study: clinical stage, 
HIV infection, EBV infection, and the number of extra-
nodal sites affected.
The knowledge of prognostic factors in ML of the oral 
cavity and the area of the head and neck is essential for 
tailoring therapeutic interventions for individual patients 
with NHL in the oral cavity. Future studies comparing 
survival comparing other factors such as molecular stu-
dies, immunophenotypic profiles, and viral responses in 
NHL in these regions may help the development of new 
therapeutic strategies.
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